In FAST study (NCT01630083), approximately 50% of patients with gastric/gastroesophageal adenocarcinoma were eligible for IMAB362 treatment based on CLDN18.2 IHC test (define as ≥40% of tumor cells with 2+ or 3+ staining intensity; ref. 5). The gene discussed is CLDN18; the disease is neoplasm.